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Endotoxin shock is a life-threatening disorder, associated with the rapid release of neutrophil enzymes, including neutrophil
collagenase/matrix metalloproteinase-8 (MMP-8) and gelatinase B/matrix metalloproteinase-9 (MMP-9). After activation, these
enzymes cleave extracellular matrix components and cytokines and thus may contribute to shock syndrome development. MMP
inhibitors have been suggested as immunotherapy of endotoxin shock. However, little is known about the therapeutic time window
of MMP inhibition. Here, a sublethal endotoxin shock mouse model was used to evaluate the effect of an MMP inhibiting peptide
(P2) after intravenous or intraperitoneal injection and to study the time window between LPS and inhibitor injections. With the
use of a specific ELISA the plasma P2 concentrations were monitored. Whereas we corroborated the treatment strategy of MMP
targeting in endotoxin shock with a new inhibitor, we also demonstrated that the time window, within which effective MMP
inhibition increased the survival rates, is rather limited.
1. Introduction
Bacteremia and septic shock are among the most frequent
causes of mortality in modern hospitals [1]. These diseases
are most often caused by bacterial superinfections or their
products, for instance, endotoxin, and form clinical exam-
ples of severe immunopathology [2, 3]. Endotoxin shock
induction is a commonly used animal model to evaluate the
protective effect of biologically active agents. During shock
syndrome development, lipopolysaccharide (LPS) activates
the inflammatory response by binding to Toll-like receptors
(TLR) on multiple leukocyte types [4]. Excessive TLR acti-
vation leads to exaggerated stimulation of leukocytes and
excessive production of inflammatory mediators, including
cytokines and enzymes [5, 6]. Since neutrophils are the most
abundant white blood cell type in the human circulation,
LPS will mainly, directly, and immediately act on these cells.
This interaction results in the release of neutrophil effector
molecules, including enzymes and reactive oxygen interme-
diates that contribute to the activation of MMPs [7]. An
important aspect of septic shock is its acuteness which may
be based on the fast release of mediators by degranulation
[5, 6]. In human volunteers and primate models, MMP-9
plasma levels were alreadymaximal at 1.5 to 3 hours after LPS
challenge [3, 5]. Effective inhibition ofMMP activities during
the early stage of endotoxin shock syndrome development
by the peptides Regasepin 1 and Regasepin 2 has been
documented [8, 9].
The peptide P2 was previously defined as an antitumor
peptide and is formed by the connection of an MMP-
inhibiting peptide sequence (Inhibitor 2) to the N-terminus
of an endostatin fragment, named ES-2 [10]. ES-2 repre-
sents 60–70 amino acids of endostatin and has antiangio-
genic activity. Inhibitor 2 was designed based on the back-
bone of the previously described MMP-inhibitory peptides
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Table 1: Peptide sequences and their IC50 values in 𝜇M against target enzymes.
Peptide name Peptide sequence MMP-8 MMP-9 TACE Reference
Regasepin 2 Pro-Pyr-Cys-Bip-Arg-Gly-Glu 10 0.8 1.5 [9]
Regasepin 1 Pro-Arg-Cys-Bip-Cys-Gly-Glu 3 1.5 5 [8]
Inhibitor 2 Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu 0.8 2.75 5.5 [11]
ES-2 Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro >500 >500 >500 [10]
P2 Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro 0.35 1.36 1.95 [10]
HM-3 Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp ND ND ND [12]
Regasepin 1 and Regasepin 2, by targeting MMP-9 and TNF-
alpha converting enzyme (TACE) [11]. The fusion peptide
P2 has a similar inhibitory profile against MMP activities as
Inhibitor 2 [10]. HM-3 is another antitumor peptide [12]. It
was formed by the connection of the RGD sequence to the
C-terminus of ES-2. HM-3 has a short in vivo half-life of only
27 minutes [12] (peptide sequences of the above-mentioned
peptides in Table 1).
Several methods exist for the determination of protein
and peptide concentrations in plasma, for example, high-
performance liquid chromatography (HPLC) [13], gas chro-
matography (GC) [14], capillary electrophoresis (CE) [15],
radioimmunoassay (RIA) [16], and mass spectrometry [8].
However, these methods are labour-intensive for sample pre-
treatment and require the availability of expensive detectors.
Enzyme-linked immunosorbent assay (ELISA) is an afford-
able and simple immunological detection method in the field
of preclinical and clinical analysis of protein and peptide
drugs [17, 18]. Therefore, to monitor the pharmacokinetics
of P2 in order to define the therapeutic window for the
treatment of endotoxin shock by MMP inhibition, we also
developed a competition ELISA for this peptide inhibitor.
2. Materials and Methods
2.1. Reagents and Animals. Peptide P2 and Inhibitor 2
(more than 96% purity) were chemically synthesized by
GL Biochem Ltd. (Shanghai). Bovine serum albumin (BSA)
and human serum albumin (HSA) were purchased from
Sigma. P2-BSA was used as the ELISA coating antigen. It
was produced by linking of P2 to BSA by reaction with a
carbodiimide reagent (kit 786-068, Boyuan Biotechnology,
China). Horseradish peroxidase-labelled goat anti-rabbit sec-
ondary antibody was purchased from Multi-Sciences Co.,
Ltd., China.
Adult female Swiss mice (6-7 weeks, 18–20 g) were pur-
chased from the Shanghai Animal Center of the Chinese
Academy of Sciences and used under the experimental ani-
mal production license: SCXK (Hu) 2012 0004. All animals
were housed in a controlled environment (25∘C; 12 h light-
dark cycle), with water and food provided freely. The authors
confirm that experiments involving animals adhered to the
institutional ethical standards of China Pharmaceutical Uni-
versity and the care of animals was independently assessed
and approved in accordance with the licensing guidelines of
China Pharmaceutical University.
2.2. Establishment of Endotoxin Shock Model
2.2.1. LD50 Determination and Intravenous Administration of
Inhibitors. Prior to formal experiments, the dosis yielding
50% lethality (LD50) was determined. Adult female Swiss
mice were placed in five groups with 4 mice per group.
Mice in Groups 1 to 5 were intravenously injected with
100 𝜇L (0.5, 1, 2, 3, or 4 𝜇g/𝜇L) LPS from E. coli serotype
0111:B4 (Sigma) dissolved in 0.9% saline, respectively. At 24
hours after administration, the survival rates in each group
were observed and the LD50 of the used Swiss mice treated
with LPS was obtained. Similar results were obtained in
independent experiments and various production lots of LPS
(Lot number 091M4031V, Lot number 012M4098V, and Lot
number 099K4025) yielded, respectively, LD50 values of 100,
50, and 50 𝜇g per mouse.
As Regasepin 2 (peptide sequence in Table 1) was found to
protect mice from endotoxin shock by intravenous injection
of 100 𝜇L (7mg/mL) Regasepin 2 (35mg/kg) 5 minutes
after intravenous injection of LPS [9], it was included here
as a positive control peptide. The protective effect of all
inhibitors was evaluated in a similar way. P2 (90mg/kg P2)
was used at a similar molar concentration as Regasepin 2.
The effect of lower dosages of P2 (30mg/kg and 10mg/kg)
was also evaluated in parallel experiments. The details of
the animal experiments, including grouping of mice, number
of mice in each group, reagent concentrations, and ways
of administration, are shown in Table 2. The peptides were
administered intravenously 5 minutes after LPS injection.
The protective effects via intravenous injection were
evaluated in groups of 6 mice, intravenously injected with
100 𝜇L (7mg/mL; 35mg/kg) Regasepin 2 or Inhibitor 2
(35mg/kg) 5 minutes after intravenous injection of LPS
(200𝜇g per mouse). The numbers of surviving mice were
recorded regularly after LPS administration. Kaplan-Meier
survival curves were generated. 𝑃 values were calculated
compared with the survival rates of the negative control
group. The experiments were performed two times.
2.2.2. Evaluation of the Protective Effect of P2 via Intraperi-
toneal Administration. The experimental details are shown
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Table 2: Peptide treatment strategy for the animal experiments in
Figure 1.
Group Peptide administration strategy
G1 (𝑛 = 12 or 15) LPS (100 𝜇L∗, iv)
G2 (𝑛 = 12) LPS (100 𝜇L, iv), 5 minutes later, Regasepin 2(100𝜇L∗∗, iv)
G3 (𝑛 = 12) LPS (100 𝜇L, iv), 5 minutes later, P2 (100𝜇L
∗∗∗,
iv)
∗LPS is dissolved in sterile 0.9% saline at a concentration of 2𝜇g/𝜇L.
∗∗Regasepin 2 was dissolved in sterile 0.9% saline at a concentration of
7mg/mL. ∗∗∗Peptide is dissolved in sterile 0.9% saline at a concentration of
17.7mg/mL for the experiment in Figure 1(a), 5.9mg/mL for Figure 1(b), and
1.97mg/mL for Figure 1(c).
Table 3: Peptide treatment strategy for the animal experiment in
Figure 4(a).
Group Peptide administration strategy
G1 (𝑛 = 16) LPS (100 𝜇L∗, iv),
G2 (𝑛 = 12) LPS (100 𝜇L, iv), 5 minutes later, P2 (100𝜇L∗∗∗, iv)
G3 (𝑛 = 12) LPS (100 𝜇L, iv), 5 minutes later, P2 (100𝜇L, iv),2 hours later, P2 (100𝜇L, iv)
∗LPS is dissolved in sterile 0.9% saline at a concentration of 2𝜇g/𝜇L.
∗∗∗Peptide P2 is dissolved in sterile 0.9% saline at a concentration of
2.0mg/mL.
Table 4: Peptide treatment strategy for the animal experiment in
Figures 4(b), 4(c), or 4(d).
Group Peptide administration strategy
G1 (𝑛 = 12 or 15) LPS (100 𝜇L∗, iv)
G2 (𝑛 = 12) LPS (100 𝜇L, iv), 5 minutes later, Regasepin 2(100𝜇L∗∗, iv)
G3 (𝑛 = 12) P2 (200 𝜇L
#, ip), wait for some time##, LPS
(100𝜇L, iv)
∗LPS is dissolved in sterile 0.9% saline at a concentration of 2𝜇g/𝜇L.
∗∗Regasepin 2 was dissolved in sterile 0.9% saline at a concentration of
7mg/mL. #The concentration of P2 was 15mg/mL; ##the time interval was
30, 60, or 90minutes for the experiments shown in Figures 4(b), 4(c), or 4(d).
in Tables 3 and 4. Regasepin 2 via intravenous injection
(35mg/kg) was used as a positive control peptide. 200𝜇L P2
(15mg/mL) was administered intraperitoneally (150mg/kg)
30, 60, or 90 minutes before intravenous LPS challenge
(200𝜇g per mouse) to evaluate the effect of P2 via this
administration route. The protective effects of a single intra-
venous injection of P2 (10mg/kg) and two times intravenous
administration of P2 (10mg/kg) with 2 hours interval were
also included and compared.
2.3. Establishment of Indirect Competitive ELISA
2.3.1. Generation of Polyclonal Antibodies Recognizing P2.
New Zealand white rabbits were subcutaneously immunized
with a conjugate between P2 and keyhole limpet hemocyanin
(P2-KLH) to produce the polyclonal antibodies. Freund
complete adjuvant (FCA) was employed in the first immu-
nization and Freund incomplete adjuvant (FIA) was used in
the subsequent booster injections. Rabbits were immunized
every three weeks with 500 𝜇g of immunogen, and blood
samples from the marginal vein of the ear were taken for
identification of seroconversion. Ten days after the final
boost, both rabbits were exsanguinated by heart puncture and
the serum was separated from blood cells by storing at 4∘C
overnight and centrifugation at 500 rpm for 10min.Then the
antibodies in this crude serumwere purified using Protein-G
affinity column and the purified antibody was used to setup
the indirect ELISA method.
2.3.2. Development of a Competition ELISA for P2. The
concentration of P2-BSA that was used to coat the plates
and the reagent concentration of the P2-specific polyclonal
antibody were optimized by two-dimensional serial dilution
tests. 96-well microtiter plates were coated with a solution of
6 𝜇g/mL P2-BSA in 0.05M sodium bicarbonate (pH 9.6) and
the plate was kept overnight at 4∘C. After washing the plate
three times, the plate was blocked with 0.1M PBS (pH 7.4)
containing 10% (V/V) skimmilk at 37∘C for 1.5 h. To perform
the competition ELISA between P2 and the immobilized P2-
BSA, P2-specific antibody (1000 times serum dilution) was
added to the wells in the presence of plasma or standard
samples at 37∘C for 1.5 h. After washing the plate three
times, 100𝜇L of horseradish peroxidase-conjugated goat anti-
rabbit IgG (1 : 2000) was added and incubated for 1 h at
37∘C. After washing three times, the tetramethylbenzidine
(TMB) substrate (100 𝜇L/well) was added and the reaction
was executed for 15min. The reactions were stopped with
2M sulfuric acid (50 𝜇L/well). The absorbance of each well
at 450 nm was detected with an automated ELISA reader.
The calibration curve was expressed according to the fact
that 1-B/B0 are linear with log C (where B0 is the OD
value in the absence of P2 in plasma, B is the OD value
at serial concentrations of P2 in plasma, and C is the P2
concentration, resp.). The indirect ELISA procedures were
conducted in duplicate with a set of standard concentrations
of P2 in diluted mouse serum in order to determine the
mathematical fitting equation and linear detection range.
Human serum albumin (HSA) and bovine serum albumin
(BSA) were used to detect the specificity of the P2 antibody.
Serial dilutions (1 ng/mL, 10 ng/mL, 100 ng/mL, 1 𝜇g/mL,
10 𝜇g/mL, 100 𝜇g/mL, and 1mg/mL) of the selected proteins
were measured by indirect ELISA. Calibrations of 1-B/B0
versus log C were done, with, in these respective conditions,
C being the concentration of BSA or HSA.
2.4. Pharmacokinetics Study of P2
2.4.1. Sample Collection. Adult female Swiss mice, 5 animals
per group, were used for the pharmacokinetic studies. P2
(90mg/kg, 30mg/kg, or 10mg/kg) was dissolved in sterile
0.9% saline and was administered intravenously. Blood sam-
ples were collected through the canthus at 0, 3, 6, 9, 12, 15,
and 30min. For intraperitoneal injection of P2, 150mg/kg P2
dissolved in 0.9% saline was administered and blood samples
were collected through the canthus at 0, 13, 20, 40, 68, 100,
127, and 168 minutes.
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2.4.2. Sample Pretreatment. Blood samples were immediately
centrifuged (12000 rpm for 30 seconds), and the supernatants
were taken and diluted 10, 30, or 300 times with PBS,
prewarmed at 80∘C in a water bath. The diluted samples
were kept at 80∘C for another 30min to remove enzyme
activity of the plasma components. Samples were dilutedwith
prewarmed PBS so that the final concentration of P2 was
within the linear range of the standard line.After another cen-
trifugation (12000 rpm for 2min), the diluted samples were
analyzed by ELISA to measure the plasma P2 concentrations.
2.5. Statistical Methods. Results were represented as mean
± SD. Statistical significance was assessed using statistics
software SPSS13.0. Two-way analysis of variance (ANOVA)
was used to test for differences between groups. For all
statistical comparisons, positive groups were compared with
negative controls, and ∗𝑃 < 0.05 or ∗∗𝑃 < 0.01 were
considered statistically significant.
3. Results
3.1. Protection from Endotoxin Shock after Intravenous P2
Injection. In endotoxin shockmodels, the survival ratemight
be influenced by LPS preparations. LD50 values of a few
LPS preparations for the same mice strain were determined
by incremental dosing. One specific batch (Lot number
091M4031V) with an LD50 of 100𝜇g per mouse was used
for the subsequent animal work. Groups of 6 mice were
intravenously injected with P2 or Regasepin 2 5 minutes
after intravenous injection of LPS (200𝜇g per mouse). The
mice were observed at regular intervals. As expected, in
three independent experiments, Regasepin 2 at 35mg/kg
displayed a significant protective effect in Swiss mice after
intravenous administration (35mg/kg) and the 𝑃 value,
compared with the corresponding negative control group,
was below 0.0005 (Figure 1(a)), 0.013 (Figure 1(b)), and below
0.0008 (Figure 1(c)). P2 at a dose of 90mg/mL also showed
a significantly protective effect with a 𝑃 value of 9.13 ×
10−7 compared with the negative control group (Figure 1(a)).
Furthermore, P2 at a dose of 30mg/kg also showed a
significant protective effect (𝑃 = 0.0054; Figure 1(b)). At a
dose of 10mg/kg (although less mice survived in G3 than in
G2 (see the tables)), P2 still showed a significant protective
effect (𝑃 = 0.0138) (Figure 1(c)).
As Inhibitor 2 has a similar structure and inhibitory
profile as Regasepin 2, the protective effect of Inhibitor 2 in
the endotoxin shock model was also evaluated. As shown in
Figure 1(d), all mice in the negative control group died 22
hours after LPS injection and Regasepin 2 and Inhibitor 2
both showed a significant protective effect (𝑃 = 0.0087 and
0.0016, resp.).
3.2. Establishment of Indirect Competitive ELISA. In order
to validate MMP inhibition in vivo, it is critical to monitor
that the inhibitor is present at sufficient concentrations. Two
rabbits were immunized with P2-KLH.The purified antibody
was used to establish a competition ELISA to detect P2 levels.
From Figure 2(a), it was deduced that the purified antibodies
from the two rabbits showed similar binding graphs to the
immobilized P2-BSA. The antibody from the first rabbit was
used in the following experiments. Two-dimensional serial
dilution was performed to select the proper coating concen-
tration of P2-BSA and the reagent concentration of anti-P2
polyclonal antibody. From Figure 2(b), the combination of
P2-BSA (1 : 100 dilution) and the antibody (1 : 1000 dilution)
gave not only a good absorption but also a good competition
by 800 ng/mL P2.The dilution for the HRP-labeled goat anti-
rabbit secondary antibody was determined to be 1 : 2000.
Furthermore, from Figure 2(c), P2 showed a good compet-
itive inhibition of antibody binding to the immobilized P2-
BSA, whereas HSA and BSA showed no inhibition even at
high concentrations.These data confirmed that the generated
antibody against P2 does not cross-react with other selected
proteins. Calibration curves for determination of P2 by the
indirect competitive ELISA were established. Satisfactory
curves were always obtainable between 50 and 3200 ng/mL
of P2 concentrations. A typical standard curve is shown in
Figure 2(d). The parameter 1-B/B0 correlated well with log C
(𝑌 = 0.393𝑋 − 0.543, 𝑅2 = 0.998). In this example, P2 was
diluted with decomplemented mouse serum that was diluted
30 times with PBS.
3.3. Pharmacokinetic Analysis of P2 in Swiss Mice after Intra-
venous Injection. We applied the competitive ELISA for a
pharmacokinetic analysis of samples that were collected after
intravenous administration of P2. After a single intravenous
injection of 100 𝜇L (17.7, 5.9, or 2.0mg/mL) P2, which corre-
sponded to the dosage of 90, 30, and 10mg/kg (see Figure 1),
wemonitored the drug concentrations in plasma until 30min
after administration. In Figure 3(a), the profiles of P2 at
a dose of 90mg/kg, averaged from five individual mice,
are shown. In Figure 3(b), the profiles of P2 concentration
versus time after intravenous injection of P2 are shown.
Intravenous administration of P2 produced an immediate
peak in plasma P2 levels inmice.The plasma P2 level dropped
rapidly within 6min after injection and then declined slowly
and progressively. For a better observation, the profiles for
the three dosages from 9 to 30 minutes were shown in
Figure 3(c).The higher dosing resulted, as expected, in higher
inhibitor concentrations. This result is in accordance with
the survival results in Figures 1(a)–1(c). From Figure 3(c),
it can be deduced that, after injection of 100 𝜇L (2mg/mL)
P2, with minimal protective effect (𝑃 = 0.0138, Figure 1(c)),
an effective P2 concentration (above 2𝜇M) still remained
in plasma for 6 minutes. This indicated that, for the used
animal model of endotoxin shock, an effective inhibition
of the relevant enzymes within the first 11 minutes (a six-
minute degradation time and a five-minute interval between
LPS and P2 administration) after LPS administration can
successfully alleviate shock syndromes and increase survival
rate of experimental mice. These data illustrate that protease
inhibition during an extremely early and short time interval
is sufficient for therapeutic efficiency in endotoxin shock.
3.4. Endotoxin Shock after Intraperitoneal Injection of P2.
The experimental strategies are shown in Tables 3 and 4. In
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Figure 1: P2 and Inhibitor 2 protect Swiss mice from endotoxin shock after intravenous administration. In all the experiments, 35mg/kg
Regasepin 2 by intravenous injection was included as a positive control peptide. The protective effects of P2 at a dosage of 90mg/kg (a),
30mg/kg (b), and 10mg/kg (c) by intravenous injection were shown. (d) The effect of 35mg/kg Inhibitor 2 by intravenous injection was
evaluated in a similar way as in panel (a) to (c). Kaplan-Meier survival curves were generated. The results of two parallel and independent
experiments were pooled (𝑛 = 12 for each condition). The details of the animal experiments were tabulated in Table 2. All peptides and 0.9%
NaCl control solution were administrated intravenously 5 minutes after LPS injection.
Figure 4(a), P2-treated mice showed a significant difference
with the LPS-treated control group, indicating that P2 at
10mg/kg protected mice from endotoxin shock. A low dose
of 10mg/kg was selected here to study longer inhibition
intervals in the case that the second intravenous injection
of P2 provided further protective effect. The rationale of the
experimental design (in G3) with two intravenous injections
was indeed to prolong P2 concentrations at inhibitory levels
in the circulation. However, the result showed that less mice
survived (in G3 than in G2). This experiment was repeated
two times with the same result. This implied that a second
intravenous injection of P2 did not improve the outcome. In
Figures 4(b), 4(c), and 4(d), groups of 6 mice were injected
intraperitoneally with P2 (150mg/kg) 30, 60, or 90 minutes
before LPS challenge. As expected, Regasepin 2 via intra-
venous administration showed a significant protective effect.
In the corresponding experiments, P2 via intraperitoneal
injection showed significant protective effects (𝑃 < 0.0004,
30 minutes before LPS challenge; 𝑃 = 0.0011, 60 minutes
before LPS challenge; 𝑃 = 0.0243, 90 minutes before LPS
challenge). The mouse survival data indicated that P2 via
intraperitoneal injection showed better protective effectwhen
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Figure 2: Establishment of the indirect ELISA for detection of plasma P2 concentrations. (a) Immunoreaction of purified antibody from
two rabbits that were immunized with P2-KLH. LgT represents the logarithm of serum dilution factors. (b) Two-dimensional serial dilution
method for selection of coating concentration of P2-BSA and reagent concentration of polyclonal anti-P2 antibody. Two columns of data
exist under each antibody dilution condition. The white panels represent absorbance after binding of the antibody to the immobilized P2-
BSA whereas the gray panels represent absorbance after binding of the antibody to immobilized P2-BSA in presence of 800 ng/mL P2 as a
competitor. (c) Antibody specificity determination. (d)The standard curve with P2 concentrations ranging from 50 to 3200 ng/mL. B0 is OD
value in the absence of P2 in plasma, B is OD value at serial concentrations of P2 in plasma, and C is P2 concentration. In this example, serial
P2 concentrations were prepared in mouse plasma that had been diluted 30 times with prewarmed PBS at 80∘C.
injection intervals between P2 and LPS decreased. All the
experiments were performed two times with reproducible
results.
3.5. Pharmacokinetic Analysis of P2 in Swiss Mice after
Intraperitoneal Injection. The developed indirect ELISA was
also used for a pharmacokinetic analysis of samples that were
collected after intraperitoneal injection of P2 (150mg/kg).
After a single intraperitoneal injection of 200 𝜇L (15mg/mL)
P2, we monitored the drug concentrations in plasma at 13,
20, 40, 68, 100, 127, and 168min after administration. In
Figure 5, the profile of P2 concentration versus time, averaged
from five individual mice, was shown. This indicated that
intraperitoneal administration produced a quick increase of
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Figure 3: Plasma concentrations of P2 versus time after an intravenous bolus injection. (a) The profiles of P2 at a dose of 90mg/kg in five
individualmicewere averaged.Thedata point at time 0 is not shown. (b)Theprofiles of P2 plasma concentrations versus time after intravenous
injection of 90, 30, or 10mg/kg P2 were shown. (c) For a clear observation of the profiles in (b), the data from time point 9 to 30 minutes were
magnified.
the P2 concentration in plasma and the average profile indi-
cated that, after 13 minutes, the concentration progressively
decreased. This result was in accordance with the survival
experiments. At 100 minutes, there was still 1.54 𝜇M or
3.63 𝜇g/mL P2 present in mice plasma, which can effectively
inhibit the secreted MMP activity. These pharmacokinetic
data are in line with the knowledge of a time window of only
10 minutes after LPS administration and thus fully explain
the survival curves obtained with P2. These results also
confirmed that peptide P2 entered quickly into the circulation
and protected mice from endotoxin shock.
4. Discussion
In line with previous knowledge [1–3], intravenous LPS
injection will immediately act on neutrophils and stimu-
late these abundant leukocytes to secrete various effector
molecules including MMP-8, MMP-9, and reactive oxygen
intermediates, which can activate pro-MMPs via a “cysteine
switch” mechanism [19]. Early inhibition of MMP activities
with peptides can successfully protect mice from endotoxin
shock [8, 9], but little is known about the pharmacological
behavior of such peptide inhibitors in vivo, after different
routes of injection. Similar molar amounts of P2 (90mg/kg)
as those of Regasepin 2 showed a significant protective
effect. Furthermore, the effect of decreasing doses of P2
was evaluated and it was found that a dosage as low as
10mg/kg P2 can still show a significant protective effect. An
indirect ELISA method with an anti-P2 polyclonal antibody
was developed to detect the plasma concentrations of P2.
It was found that the plasma concentrations of P2 quickly
decreased and for the dosage of 10mg/kg P2, effective plasma
concentration lasted for only 6 minutes. Even for the dosage
of 90mg/kg P2, effective plasma concentration of P2 lasted
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Figure 4: P2 protects Swiss mice from endotoxin shock after intraperitoneal administration. For all the experiments, 35mg/kg Regasepin 2
via intravenous injection was included as a positive control. (a) A single intravenous injection of 10mg/kg P2 protected mice from endotoxin
shock, whereas two injections of 10mg/kg P2 at two hours interval decreased the survival rate of the mice. The protective effects of P2 at
a dosage of 150mg/kg via intraperitoneal injection 30 minutes (b), 60 minutes (c), and 90 minutes (d) before intravenous injection of LPS
(200 𝜇g per mouse) were shown. Kaplan-Meier survival curves were generated.The results of two parallel and independent experiments were
pooled. The details of the animal experiments were tabulated in Tables 3 and 4.
less than 30 minutes. These results illustrate the need for
immediate medical action, within 10 minutes, in all cases of
endotoxinemia and explain partially the failure of therapies
and high patient mortality rates of about 35%, even with
the best medical cares in the most specialized hospitals.
Indirect experimental evidence for this paradigm stems from
baboon studies in which serum levels of MMP-9 quickly
increased and peaked at 2-3 hours [5]. Pugin et al. confirmed
that LPS can induce a rapid (within 20 minutes) release of
MMP-9 zymogen in whole human blood [20], and Dubois
et al. further confirmed that neutrophils contributed to the
increase of pro-MMP-9 [6]. Worth of notice is the effective
dose of LPS. In the baboon model [5], whole bacteria were
injected and it may take some time to accumulate enough
LPS or peptidoglycan to stimulate neutrophils. In the latter
case, during the gelatin zymography analysis of conditioned
plasma after LPS treatment, the LPS dosage was 100 pg/mL
and 1 ng/mL. The time for pro-MMP-9 levels to peak after
LPS treatment was 1 hour for 100 pg/mL LPS treatment and
only 20 minutes for 1 ng/mL LPS treatment. In our endotoxin
shock model, 200𝜇g LPS was intravenously injected into
mice. Inhibition of MMP activities within 11 minutes (a six-
minute degrading time and a five-minute interval between
LPS and peptide administration) is enough to protect mice
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Figure 5: Plasma concentrations of P2 versus time after a single
intraperitoneal injection. The profiles of P2 (150mg/kg) in five
individual mouse were averaged.
from lethal endotoxin shock in this experimental setting.
Our data, unfortunately, also demonstrate the limited time
interval to act in clinical settings.
Second, the MMPs degranulated by neutrophils, for
example MMP-8 and MMP-9, are released proenzymes.
During endotoxin shock syndrome development, pro-MMP-
8 and pro-MMP-9 may be activated by reactive oxygen
intermediates [7].These reactive oxygen intermediates (ROS)
have a very short lifetime in plasma and they can be easily
neutralized by reducing agents. P2 with a free cysteine in its
sequence possesses reducing properties. Even if P2 would be
cleaved by abundant proteases, the cysteine residue would
still exhibit its reducing activities. Third, the Inhibitor 2 part
of P2 also inhibits MMP-8 and MMP-9 activities [11], even if
the ES-2 part of P2 would be cleaved off (Figure 1(d)).
The half-life of peptide HM-3 that also contains the ES-
2 sequence (see Table 1) was determined to remain only 27
minutes in the rat circulation [12]. The pharmacokinetics
of P2 by intraperitoneal injection was also investigated. The
peak level of P2 by intraperitoneal injection was reached
within 13 minutes (Figure 5). After intraperitoneal injection,
P2 entered quickly into the circulation and thereafter its
plasma concentration gradually decreased. At 100 minutes
after ip injection, the plasma concentration was decreased to
1.54 𝜇M, which means that 90 minutes might be the largest
therapeutic interval for P2 at this dosage. Future develop-
ments may improve these pharmacological parameters. For
instance, the pharmacokinetic character of peptides can be
improved by polyethylene glycol (PEG) modification. HM-
3 (for sequence, see Table 1) is an antitumor peptide with a
half-life of 27 minutes in the rat circulation [12]. After N-
terminal modification of the peptide with a PEG molecule of
20 kDa, PEG-HM-3 showed a clearance half-life of 20 hours
[21, 22]. Although, after modification of P2 with PEG in a
similar way, the PEG-P2 may have a longer plasma half-life
and easily pass through blood vessels and get into tissues, the
aspect of a limited therapeutic time window will remain an
issue. However, many other inflammatory diseases exist with
larger time windows [23] and these might benefit from the
new insights presented here.
In conclusion, endotoxin shock is a life-threatening
immunopathological disorder and early inhibition of MMPs,
which are degranulated by neutrophils after LPS stimulation,
protects mice from death. Furthermore, the present study
defined the strictly limited therapeutic time window in the
event of lethal endotoxin shock induction. This information
not only is interesting from an immunopathological point of
view but also has clinical consequences.
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